Inside the research
CVS Health Corporation
CVS Research profile · latest available data
Price overview
$87.85
▼ -1.28 (-1.4%)
| 52w hi | $109.92 |
|---|---|
| 52w lo | $69.04 |
| Vol | 7.90M |
| As of | 28 Sep 2026 |
The Verdict
Our score +0.08
| Short | -0.20 |
|---|---|
| Medium | +0.21 |
| Long | +0.37 |
computed 2026-09-28
Key fundamentals
CVS Health Corporation
Healthcare · Healthcare Plans
| Market cap | $112.36B |
|---|---|
| Enterprise value | $176.54B |
| Trailing P/E | 23.18x |
| Forward P/E | 10.30x |
| EV / EBITDA | 10.58x |
| P / S (ttm) | 0.27x |
| Profit margin | 1.2% |
| Return on equity | 6.2% |
| Revenue growth | +7.1% |
| Earnings growth | +188.8% |
| Debt / equity | 95.50 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.28 | |
| Sector | +0.09 | |
| Technical | -0.09 | |
| Earnings | +0.00 | |
| Sentiment | -0.01 |
macro × 1.00 · 2026-09-28
Business overview
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Risk Metrics
| Beta vs SPX | 0.30 |
|---|---|
| Corr SPX | 0.14 |
| Annual vol | 34.6% |
| Annual ret | +27.1% |
| Sharpe | 0.78 |
| Max DD | -35.1% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $100.04 |
|---|---|
| High / Low | $140.00 / $79.00 |
| Median | $100.00 |
| Analysts | 26 |
| Strong Buy | 7 | |
|---|---|---|
| Buy | 18 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | Wells Fargo | → Overweight |
| 2026-05-07 | UBS | → Buy |
| 2026-05-07 | Truist Securities | → Buy |
| 2026-05-07 | RBC Capital | → Outperform |
| 2026-05-07 | Evercore ISI Group | → Outperform |
| 2026-05-07 | Barclays | → Overweight |
Officers & Board
| CEO | David Joyner since 2024 |
|---|---|
| Director | Karen S. Lynch since 2021 |
| Director | Roger N. Farah since 2018 |
| Director | Fernando Aguirre since 2018 |
| Director | Edward J. Ludwig since 2018 |
| Director | Mary Lovelace Schapiro since 2017 |
| Director | Alecia A. DeCoudreaux since 2015 |
| Director | William C. Weldon since 2013 |
| Director | Nancy-Ann DeParle since 2013 |
| CEO | Larry Merlo since 2011 |
| Director | Anne Finucane since 2011 |
| Director | Jean-Pierre Millon since 2007 |
| Director | C. David Brown II since 2007 |
| Director | Mark T. Bertolini 2018–2020 |
| Director | Richard M. Bracken 2015–2020 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-05-18 | Officer / Director Change, Shareholder Vote | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-03-19 | Officer / Director Change | read |
| 2026-02-10 | Earnings Release, Exhibits | read |
| 2025-12-09 | Reg FD Disclosure, Exhibits | read |
| 2025-11-20 | Other Material Event, Exhibits | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-09-22 | Other Material Event, Exhibits | read |
| 2025-08-15 | Other Material Event, Exhibits | read |
| 2025-07-31 | Earnings Release, Exhibits | read |
| 2025-05-20 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | Clark James David | SVP, Cont & Chief Acct Of | Withheld for tax | 454 | $41.30K |
| 2026-05-31 | Newman Brian | EVP, Chief Financial Offi | Withheld for tax | 2.48K | $225.45K |
| 2026-05-31 | Compton-Phillips Amy | EVP, Chief Medical Office | Withheld for tax | 7.62K | $693.09K |
| 2026-05-21 | AGUIRRE FERNANDO | Disposal | 1.56K | $146.14K | |
| 2026-05-20 | AGUIRRE FERNANDO | Disposal | 30.44K | $2.85M | |
| 2026-05-14 | AGUIRRE FERNANDO | Grant | 1.56K | $151.85K | |
| 2026-05-14 | Balser Jeffrey R. | Grant | 2.06K | $199.93K | |
| 2026-05-14 | KIRBY J SCOTT | Grant | 1.45K | $140.58K | |
| 2026-04-01 | Mandadi Tilak | EVP, Chief Exp & Tech Off | Withheld for tax | 3.63K | $263.43K |
| 2026-04-01 | Nelson Steven H | EVP and President, Aetna | Withheld for tax | 2.43K | $176.30K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 97.1% |
| HHI | 3,646 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $6.24B | 60.28M |
| Fidelity / FMR LLC | $2.99B | 28.92M |
| Citadel Advisors | $1.06B | 10.29M |
| Capital Research / Capital World | $796.46M | 7.70M |
| AQR Capital Management | $248.94M | 2.41M |
| Millennium Management | $246.47M | 2.38M |
| Renaissance Technologies | $45.62M | 441.02K |
| Bridgewater Associates | $45.62M | 440.97K |
| T. Rowe Price Group | $2.50M | 24.20M |
As of 2026-06-30
Connections
Subsidiarys: CVS Pharmacy
Customers: Care Benefits Pricing For Co
Dividends
| Yield (TTM) | 2.27% |
|---|---|
| $ / share (TTM) | $2.00 |
| 5y CAGR | +5.9% |
Annual dividend per share
| 2021 | $2.00 |
|---|---|
| 2022 | $2.20 |
| 2023 | $2.42 |
| 2024 | $2.66 |
| 2025 | $2.66 |
| 2026 | $1.33 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $16.80M | Department of Health and Human Services | BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEI |
| $5.48M | Department of Health and Human Services | CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EF |
| $1.73M | Department of Health and Human Services | BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEI |
| $1.38M | Department of Health and Human Services | CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EF |
| $498.15K | Department of Health and Human Services | CVS HEALTH CLINICAL TRIAL SERVICES LLC TO PROVIDE CLINICAL DECISION SUPPORT TO A |
| $26.60K | Department of Justice | PRICE BASED ON 3 TABS DAILY @ $161.52 PER TAB FOR 60DAYS |
| $19.98K | Environmental Protection Agency | COVID TESTING VOUCHERS WITH CVS |
| $14.52K | Department of Justice | CVS HEALTH CORPORATION DBA CAREMARK LLC, (1) REMODULIN 5MG/ML VIAL, FY25 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $372.81B | +8.7% | |
| Gross profit | $28.55B | +7.4% | |
| Operating income | $8.52B | +2.3% | |
| Net income | $8.34B | +12.2% | |
| Cash from ops | $13.43B | +7.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 28 | $89.51 | $90.01 | $87.84 | $87.85 | 7.90M |
| Sep 25 | $85.35 | $89.35 | $84.70 | $89.13 | 15.77M |
| Sep 24 | $85.83 | $86.01 | $84.50 | $85.05 | 7.38M |
| Sep 23 | $86.70 | $86.98 | $85.67 | $85.86 | 7.31M |
| Sep 22 | $87.69 | $88.28 | $86.68 | $87.10 | 8.71M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →